http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2012003633-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_add9e4fdc85250f33124ecf26dfc9520 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 |
filingDate | 2012-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bd2ccfd8bb5ab0b13bc11f0ae33ec36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ec736b2f569528419cfc2336050c48b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1334481937639102b6a016161a3a4131 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c105b45992a4fd2708b6f99ec26f725 |
publicationDate | 2013-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | MX-2012003633-A |
titleOfInvention | GOLD NANOPARTICLES RADIOMARCATED WITH 99MTC AND CONJUGATED TO PEPTIDES C [RGDFK (C)] AS A NEW RADIOPHARMACO FOR THE IN VIVO DETECTION OF ANGIOGENESIS. |
abstract | This invention relates to a new heterofunctional, multimeric and multivalent radiopharmaceutical of gold nanoparticles radiolabelled with technetium-99m (99mTc) and conjugated to hundreds of cycle peptides [Arg-Gly-Asp-D-Phe (Cys)] (c [RGDfK ( C)]) as an agent for the in vivo detection of angiogenesis in the early diagnosis of aggressive rapidly growing tumors and metastases, such as breast cancer and glioblastomas, by molecular imaging techniques in nuclear medicine. The object of this invention is to provide a new specific radiopharmaceutical (molecular target radiopharmaceutical) for the in vivo detection of angiogenesis (overexpression of integrin at (v) ß (3)) totally different from those currently on the market. . |
priorityDate | 2012-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 80.